Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic Cooperation

Racca, Patrizia; Fanchini, Laura; Caliendo, Virginia; Ritorto, Giuliana; Evangelista, W.; Volpatto, Roberta; Milanesi, E.; Ciorba, Angelica; Paris, Myriam; Facilissimo, Ivan; Macripò, Giuseppe; Clerico, Mario; Ciuffreda, Libero

doi:10.3816/ccc.2008.n.007

Cited by 45 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rash occurs predominantly in areas with a high density of sebaceous glands (scalp, face, upper chest, and back) and can be quite painful or pruritic. Initial cultures of the pustules are sterile, indicating that this reaction is not a skin infection; rather, it represents an intrinsic side effect of EGFR inhibitor treatment [5,6].…”

Section: Introductionmentioning

confidence: 99%

EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections

Braden

Anadkat

2016

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections

Braden

Anadkat

2016

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…This partnership requires uniform cataloging and grading of AEs for effective communication, better delivery of interventions, and appropriate supportive measures. 5 This article will describe the dermatologic AEs provided in Common Terminology Criteria for AEs (CTCAE) Version 4.0 (CTCAE v4.0).…”

mentioning

confidence: 99%

Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

Chen

Setser

Anadkat

et al. 2012

Journal of the American Academy of Dermatology

271

211

View full text Add to dashboard Cite

“…Data show that there is a positive correlation between the development and severity of dermatological reactions and the clinical response to the EGFR inhibitor treatment [19,20]. Furthermore, the medial survival time is longer in patients with skin lesions.…”

Section: Discussionmentioning

confidence: 99%

Effective therapy of epidermal growth factor receptor inhibitor-associated dermatologic side effects in a patient with metastatic colorectal cancer: a and review of literature

Góralczyk¹,

Sokołowska‐Wojdyło²,

Kowalczyk³

et al. 2012

pdia

View full text Add to dashboard Cite

A Ad dd dr re es ss s f fo or r c co or re es ss sp po on nd de en nc ce e: : Alicja Góralczyk, Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, 7 Dębinki, Poland, phone Case report A b s t r a c tOverexpression and impaired signaling of the epidermal growth factor receptor (EGFR) are involved in the cancerogenesis. The EGFR inhibitors such as cetuximab have shown efficacy in the targeted therapy of neoplasm. The acneiform rash has been revealed as the most common side effect of treatment, usually occurring within 2 weeks after therapy onset. We report perifollicular pustules and papules with impetiginization in a 63-year-old patient with metastatic colorectal cancer treated with cetuximab. The neoplasm was diagnosed in 2008 and treated surgically (resection of the sigmoid). After 3 years, a combined therapy was administered due to the disease progression. It consisted of cetuximab and FOLFOX (Folinic acid, Fluorouracil, Oxaliplatin) chemotherapy regimen. The effective dermatologic management (with systemic doxycycline and topical tacrolimus and fusidic acid) of the skin toxicity allowed for maintenance of oncologic treatment. Despite the proper dermatological therapy, the described side effects may persist, and the exacerbation of skin lesions can cause discontinuation of treatment of cancer with those modern biological agents (EGFR inhibitors and other kinase inhibitors). When discontinuation is not necessary -cutaneous symptoms adversely affect the quality of life. However, there are reports that recognition of the skin lesions in the course of the above therapies is a good prognostic factor, confirming effectiveness of treatment. Moreover, the association between genetic polymorphisms, the risk of treatment adverse effects and the response of the tumor to monoclonal antibody targeted therapy is well established. This leads to the increasing role of pharmacogenetics in the management of neoplasms. K Ke ey y w wo or rd ds s: : epidermal growth factor receptor inhibitors, cetuximab, dermatologic toxicity, papulopustular rash.

show abstract

Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic Cooperation

Cited by 45 publications

References 27 publications

EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections

EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections

Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0

Effective therapy of epidermal growth factor receptor inhibitor-associated dermatologic side effects in a patient with metastatic colorectal cancer: a and review of literature

Contact Info

Product

Resources

About